LGND · Ligand Pharmaceuticals

The thesis

Ligand Pharmaceuticals is more likely than not to beat the S&P 500 over the next three months. Royalty income on other companies' drugs is growing faster than expected, and the 8 December 2026 Investor Day decides whether the new five-year outlook and the $1.50 of 2027 adjusted earnings per share projected from the XOMA acquisition hold.

Ligand's 29 October 2026 report showed third-quarter royalty revenue of $70.3 million, up 51% from $46.6 million a year earlier. Royalties from assets owned before XOMA rose 25% to $58.1 million, and XOMA assets added $12.3 million (earnings call). Full-year adjusted EPS guidance rose to $9.50–$9.75 from $9.00–$9.50. Royalty guidance of $225–$250 million and total revenue guidance of $270–$310 million were reaffirmed (Ligand 8-K).

The view here is that the unchanged royalty range understates the fourth quarter. That view fails if full-year royalty revenue lands in the lower half of the range.

The shares closed at $316.27 on 12 November 2026, up from $299.00 on 5 November 2026, the session after the report. The price already reflects the beat: the close is 3.2% below the 52-week high of $326.63 (intraday, 8 July 2026) and above the 50-day average of $301.33.

Bullish and bearish views on Ligand Pharmaceuticals Incorporated

The bull case on Ligand Pharmaceuticals Incorporated (LGND), in brief: Filspari is now the largest royalty. The bear case: reported earnings showed a loss.

Bull case

• Filspari is now the largest royalty. Ligand estimated its third-quarter Filspari royalty at $16.8 million, up 85%, ahead of Kyprolis at $10.5 million (earnings call, 29 October 2026). Travere reported on 2 November 2026 that U.S. Filspari net sales rose 120% to $200.2 million.
• Guidance looks cautious against the run rate. Nine-month royalty revenue was $161.3 million against the $225–$250 million full-year range (Ligand 8-K, 29 October 2026). The chief financial officer said on the call the company has "a high level of confidence" in the mid-to-upper part of the implied fourth-quarter range.
• The XOMA earnings target was reaffirmed. Management said on the 29 October 2026 call there were "no changes" to the $1.50 of adjusted EPS projected for 2027. XOMA closed on 14 July 2026, so the fourth quarter of 2026 is its first full quarter inside Ligand.
• Analyst targets rose after the report. Citigroup raised its target to $402 on 5 November 2026. Barclays kept Overweight and raised its target to $350 on 11 November 2026. RBC moved to $357 from $345 and Oppenheimer to $346 from $334 on 30 October 2026 (Benzinga headlines).
• Capital is available for new royalties. Ligand reported about $750 million of deployable capital on 29 October 2026, including $447.4 million of cash and short-term investments at 30 September 2026. The chief executive said on the call that deploying "somewhere below $200 million" a year would sustain growth for a significant period.

Bear case

• Reported earnings showed a loss. The third-quarter net loss under generally accepted accounting principles was $28.5 million, or $1.43 per share, against net income of $117.3 million a year earlier (Ligand 8-K, 29 October 2026). Total revenue and income fell 32% to $78.7 million because the prior year included $53.1 million of Pelthos income.
• Inventory lifted some Filspari sales. Travere said on its third-quarter call that specialty pharmacy inventory above historical levels contributed about $8 million of net sales (reported 2 November 2026). Ligand's $16.8 million royalty estimate preceded Travere's report, and any difference is corrected in the fourth quarter.
• The oldest large royalty is shrinking. Amgen reported Kyprolis sales of $330 million for the third quarter of 2026, down 8% from $359 million a year earlier (Amgen 10-Q).
• Non-royalty lines are lumpy. Third-quarter Captisol sales were $7.9 million and contract revenue was $0.5 million against a $10–$20 million full-year contract range (Ligand 8-K, 29 October 2026). The fourth quarter has to carry most of that range.
• Cash is flowing into Pelthos. Ligand agreed to buy $33.75 million of Pelthos Series B preferred shares and warrants, $30.075 million of it in cash at closing (Schedule 13D/A, filed 3 November 2026). Cash and short-term investments had already fallen to $447.4 million at 30 September 2026 from $733.5 million at 31 December 2025.

Price setup

The shares closed at $316.27 on 12 November 2026, after $316.83 on 11 November 2026 and $314.16 on 10 November 2026. The 50-day average is $301.33 and the 200-day average is $257.8. The three-month change is 7.4%, from a close of $294.60 on 14 August 2026. The 52-week closing low is $181.65 on 12 February 2026.

The shares rose from $299.00 on 5 November 2026 to $306.20 on 6 November 2026 and then to $314.15 on 9 November 2026. The 52-week intraday high of $326.63 from 8 July 2026 is the nearest prior high above the shares.

Insiders have sold into the rise. Director Jason Aryeh reported an open-market sale of 3,000 shares at an average $320.05 on 10 November 2026, after sales of 282 shares at $319.99 on 4 November 2026 and 2,111 shares at an average $320.30 between 30 October 2026 and 2 November 2026 (SEC Form 4 filings). Chief legal officer Andrew Reardon sold 5,000 shares at an average $313.22 on 2 November 2026 under a Rule 10b5-1 plan, after similar sales on 2 October 2026 and 3 September 2026 (SEC Form 4 filings).

The shares trade above the roughly $294 level at which management said warrants tied to the 2030 convertible notes begin to dilute.

Catalysts ahead

• 30 November 2026: Ligand investor meetings at the Miami Biotech Collective Summit. Management commentary on fourth-quarter royalties could show where the year lands within the $225–$250 million royalty guidance.
• 8 December 2026: Ligand Investor Day, 10:30 a.m. ET, with an updated five-year outlook. It is the next dated check on the projected $1.50 of 2027 XOMA adjusted EPS and resets long-term royalty growth expectations.
• ~15 December 2026 (est.): Rezolute topline results for ersodetug in tumor hyperinsulinism, guided for mid-December 2026. It is the nearest clinical readout for a partnered program and tests the value of Ligand's pipeline royalties.
• 1 February 2027: Outside date for the Pelthos and Castle Creek merger, extendable to 31 March 2027. Completion decides whether Ligand's Pelthos capital commitment proceeds as described in the 3 November 2026 Schedule 13D/A.
• 28 February 2027: FDA decision date for Palvella's Qtorin rapamycin in microcystic lymphatic malformations. An approval would allow a potential first-half 2027 launch; a rejection would remove that expected new royalty stream for now.

What would change the view

A weekly close below $262, the price at which Ligand disclosed share repurchases on 6 August 2026, which would show the shares giving back the recent gains. A cut of 2026 royalty revenue guidance below $225 million, or a lower 2027 XOMA adjusted earnings outlook on 8 December 2026, would also show the case failing.

The risks this note tracks, each with what would confirm it:

• Royalty growth fails to support the annual outlook reaffirmed on 29 October 2026. Confirmed by: Ligand cuts full-year 2026 royalty revenue guidance below its published $225 million floor, or the full-year result lands in the lower half of the $225–$250 million range.
• XOMA contributes less than management projected and reaffirmed on 29 October 2026. Confirmed by: the 8 December 2026 outlook reduces or withdraws the roughly $1.50 of adjusted EPS projected for 2027.
• Filspari's third-quarter strength partly reflects specialty pharmacy inventory that later unwinds. Confirmed by: Travere's next quarterly report shows Filspari net sales below the $200.2 million reported for the third quarter of 2026 or describes an inventory drawdown.
• Declining Kyprolis sales outweigh growth from newer royalty products. Confirmed by: Amgen reports Kyprolis sales below the $314 million of the second quarter of 2026 while Filspari growth slows sharply from 120%.
• The Pelthos and Castle Creek transaction ties up capital or fails to close. Confirmed by: the merger is not completed by the 1 February 2027 outside date, extendable to 31 March 2027, as described in the 3 November 2026 Schedule 13D/A.

What it trades with

Ligand's income tracks partner drug sales more than broad biotech trial news. Travere's Filspari and Amgen's Kyprolis are the two largest royalties, so Travere's quarterly reports move the read on Ligand directly.

Pipeline events at partners such as Rezolute and Palvella add event risk around specific dates. The Pelthos stake, enlarged by the preferred share purchase agreed on 30 October 2026, links part of Ligand's balance sheet to a small commercial company. The convertible notes and warrants add a dilution link to Ligand's own share price above roughly $294.